The humanized αVβ6 integrin-blocking antibody STX-100, which inhibits the activation of latent TGF-β on epithelial cells, is currently being examined in a phase II trial in IPF patients[24,99]. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.